Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-87562761
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Unspecified (not Yet Disclosed; See Process)
01
Overview
JNJ-87562761 is an investigational antineoplastic agent being developed by Janssen Research & Development for the treatment of relapsed or refractory multiple myeloma. It is a new molecular entity currently in Phase 1 clinical trials. The precise mechanism of action and molecular target have not been publicly disclosed as of June 2025. The drug is being evaluated in first-in-human studies to determine its recommended Phase 2 dose, safety, and tolerability in patients whose disease has returned after prior therapy or has not responded to standard treatments[1][2][3][4].
Beyond the preview
Go deeper on JNJ-87562761.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-87562761.